Navigation Links
CSL Behring Partners with Pro Supercross Racer Carl Schlacht to Encourage Those with Primary Immunodeficiency to be a "ChamPIon"
Date:12/13/2012

I Am a ChamPIon website offers information about the condition and identifying the warning signs for diagnosis. At www.IamaChamPIon.com you can also watch a video of Carl on the race track and discussing his journey to becoming a professional Supercross racer despite PI.  

About Primary Immunodeficiencies   
Nearly 150 types of PIs exist. For individuals with PI, many of them children, infections may not improve as expected with usual treatments and may even keep returning. As a result, patients may face repeated rounds of antibiotics or hospitalization for treatment. Repeated infections can lead to organ damage, which over time can become life-threatening. Some infections, such as meningitis, may even result in death.

Collectively, PIs affect an estimated 10 million people worldwide. Due to the X-linked inheritance in many PI syndromes, more males are affected than females.  For more information on PI, please visit www.IamaChamPIon.com or contact the leading PI patient advocate groups in the U.S., the Immune Deficiency Foundation and the Jeffrey Modell Foundation.

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL B
'/>"/>

SOURCE CSL Behring
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care
2. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
3. Medical Experts Who Participated in CSL Behrings Key Issues Dialogue Prefer Albumin for Fluid Management
4. CSL Behring Awards LEAD Grant to Patient Organizations to Educate Constituents on State Insurance Exchanges
5. CoreLab Partners, Medical Image Assessment Experts, Announces Its Entry Into the Early Alzheimers Imaging Market Space
6. Veterinary Bioscience Institute (VBI) and a-tune software, Inc. Partnership
7. Chimerix To Present At Therapeutic Area Partnerships Meeting
8. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
9. Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings
10. Bluechiip Signs Strategic Partnership with Gentris Corporation
11. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 This report is ... Tubing industry. For an overview analysis, the report ... industry chain structure, industry overview, policy analysis, and ... industry has witnessed rapid development with key ... acquisitions. This report mentions quartz tubing upstream raw ...
(Date:12/17/2014)... Diego, CA (PRWEB) December 17, 2014 ... and activation agency and member of the Huntsworth Health ... Gonzales to its executive team. In her role, Gonzales ... , “We are incredibly honored to welcome a ... Agency Chief and CEO, Gaëtan Fraikin. “She is a ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that the ... PVM technology , is now available. The new ... continuously captures high-resolution images under a wide range ... a report pairing the most relevant images to ... compelling blend of high resolution images and trend ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... Oct. 23 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) ... Diego on Tuesday, October 28, 2008 at 10:30 a.m. ... and Chief Financial Officer, will,be providing a corporate overview., ... a recording will be made,available following the event. The ...
... Sciences,Holdings, Inc. (Nasdaq: ADLS ) a biopharmaceutical company ... in the,therapeutic areas of infection, cancer and respiratory diseases, ... Bank to increase,its line of credit from $4 million ... by 12 months to January 1, 2011. The closing ...
... Oct. 23 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ... care by developing novel medicines in the areas ... results and,highlights for the third quarter ended September ... progress in both of our hepatitis C,development programs," ...
Cached Biology Technology:Advanced Life Sciences Completes Debt Transaction 2Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 2Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 3Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 4Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 5Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 6Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 7Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 8
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That ... known for quite a while. Hypertension – the medical term ... disease in the early 1800s, and the inflatable cuff that,s ... That doesn,t, however, mean there,s nothing new about hypertension, ... punctured some long-held beliefs about the condition and the best ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... the University of California, San Diego (UCSD) Skaggs School ... for developing a human vaccine to prevent against Human ... a type of herpes virus, is the leading viral ... patients with compromised immune systems. The body’s natural ...
... the first time anywhere, a researcher at the Hebrew University ... of neurons in the brain of a mammal. , ... Alexander Silberman Institute of Life Sciences at the Hebrew University, ... develop from an undifferentiated cellular sphere into a rich and ...
... lethal toxin is revealed today. This toxin is the one real ... kg — the weight of two bags of sugar — is ... of the same toxin are used in medical treatments, one of ... C. botulinum doesn’t have subtle tools to evade our human defences ...
Cached Biology News:New vaccine prevents CMV infection and disease in mice 2New vaccine prevents CMV infection and disease in mice 3A first -- Hebrew University scientist observes brain cell development in 'real time' 2Genome of Clostridium botulinum reveals the background to world's deadliest toxin 2Genome of Clostridium botulinum reveals the background to world's deadliest toxin 3
Mouse monoclonal [GB3] to Kalinin ( Abpromise for all tested applications). entrezGeneID: 3918 SwissProtID: Q13753...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: